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HM2
MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN
ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN
THE UNITED STATES
Mayo KW, Glass H, Lee D
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVE: An absence of the understanding of the variables
inﬂuencing physician prescribing behavior has limited the ability
of pharmaceutical manufacturers to optimize resources dedi-
cated to marketing newly launched products. This investigation
ﬁlls a void by investigating the relative inﬂuence of ﬁve sets of
predictors upon the likelihood of a physician to adopt a new
product. METHODS: The prescribing behavior of 3646 physi-
cians was examined for the ﬁrst 18 months after drug launch for
32 new drugs in 7 chronic disorders entering the market between
1997 and 2000. Two OLS regression models were derived—one
examining innovative, ﬁrst in class, drugs and the other exam-
ining follow-on products. The models utilized two dependent
variables, the total number of prescriptions written for the new
drug in the 18 months following launch and the incremental
number of prescriptions written by the physician from the
company marketing the new product. RESULTS: The models
examined the relative importance of ﬁve types of variables,
physician demographics, physician practice data, physician pre-
scribing patterns prior to the new product launch, level of mar-
keting support from the launch company and the relative
product price. The relative importance of the variables differed
appreciably between the two type drugs. CONCLUSIONS:
Physician Pre-Launch Company Prescribing Loyalty is the most
signiﬁcant predictor of the adoption of innovative drugs, while
Marketing Power and Price are the most signiﬁcant predictors of
the adoption of follow on products. This investigation provides
OLS regression models for the optimization of marketing
resources.
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PREDICTING PHARMACY COSTS USING HEALTH-RELATED
QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN
ADULT ASTHMATICS
Meyer C, Liberman J, Cooper D, Kalmanowicz J, Chaudry S
AdvancePCS, Hunt Valley, MD, USA
OBJECTIVE: To investigate if a health-related quality of life
(HRQOL) measure can predict pharmacy costs in insured adult
asthmatics independently and in conjunction with a baseline
pharmacy claims risk index and prior pharmacy costs.
METHODS: Historical cohort analysis of pharmacy claims and
HRQOL. Asthmatics were invited to complete the SF-36 quality
of life instrument between May 12, 2001 and November 30,
2002. Pharmacy claims for the year prior to this interview were
used to derive baseline measures of the AdvancePCS pharmacy
claims health risk index and prior pharmacy costs. The study’s
outcome measure, pharmacy costs in the year following the base-
line interview, was calculated for those who remained eligible for
pharmacy beneﬁts during the entire study period. Correlation
statistics were calculated. Linear regression modeling evaluated
the association between the outcome measure and each SF-36
domain, the risk index, prior costs, member sex, and age at base-
line. RESULTS: A population of 247 adult asthmatics from a
million-member, Mid-Atlantic health plan was included. Follow-
up year pharmacy costs were moderately correlated with the
pharmacy risk index (Spearman +0.576, p < 0.001) and weakly
negatively correlated with the physical summary score (Spear-
man -0.340, p < 0.001). However, prior pharmacy costs had the
strongest correlation (Spearman +0.87, p < 0.001). The physical
summary score was a signiﬁcant predictor of next year’s phar-
macy costs (Coefﬁcient -110.92; p < 0.001) after adjustment for
age in linear models (R2 = 0.134). However including the phar-
macy risk index (Coefﬁcient 72.770; p = 0.06) and prior phar-
macy costs (Coefﬁcient 0.948; p < 0.001) vastly improved the
explanation of variation in follow-up pharmacy costs (R2 =
0.774) and eliminated the independent signiﬁcant effect of the
physical summary score (Coefﬁcient -8.236, p = 0.518). Similar
removal of signiﬁcance occurred with other SF-36 domains after
adjusting for claims measures. CONCLUSIONS: While HRQOL
independently predicts follow-up costs, it does not improve pre-
dictive models using prior pharmacy utilization in this study
population of adult asthmatics.
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HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING
DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL
TRIAL IN PARKINSONS DISEASE
Noyes K, Holloway RG, Dick AW
University of Rochester School of Medicine, Rochester, NY, USA
OBJECTIVES: Subject attrition is unavoidable in long-term clin-
ical trials. Using various assumptions about missing data, this
study estimates incremental cost-effectiveness ratios (ICERs) and
welfare (W) consequences of two drug therapies in patients with
early Parkinson’s disease (PD). METHODS: Three hundred one
subjects with PD were randomized to initial pramipexole or lev-
odopa and followed every 3-months over a 4-year period. Health
care resource use was measured and costed using a variety of
sources. Quality of life (Qol) was measured using a visual analog
scale. Using a multivariate ﬁxed effects model, we imputed
missing Qol and cost data and calculated the 4-year total QALYs
and costs for each treatment arm. The ICER and the welfare (W)
estimates, using $50K as a cost of QALY, were bootstrapped to
calculate the standard errors. We conducted a sensitivity analy-
sis on the ICER and the W under optimistic and pessimistic
assumptions of a subject’s Qol after dropout based on the trends
estimated from the multivariate analysis. The slope of the post-
dropout Qol was modiﬁed based on the beta coefﬁcient for the
dummy variable indicating last visit before dropout. RESULTS:
The base case cost-effectiveness was $32,107/QALY and welfare
enhancement due to initial pramipexole versus levodopa was
$2748 (SD 4526). If subjects were to decline after dropout, the
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